Once-daily treatment approved for COPD
May 1st 2014FDA approved umeclidinium (Incruse Ellipta, GlaxoSmithKline) once-daily anticholinergic for long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
Knowledge of MATs key to overcoming opioid abuse challenges
April 29th 2014The biggest challenge in tackling opioid abuse is lack of awareness and understanding of addictive diseases, as well as misinformation and negative perceptions of medication-assisted therapies (MATs), according to a recent opinion article published in the New England Journal of Medicine.
FDA defends Zohydro approval in opioid abuse debate
April 29th 2014FDA Commissioner Margaret A. Hamburg, MD, defended the agency’s approval of the powerful opioid Zohydro ER (hydrocodone bitartrate) extended-release capsules, explaining that its highest dose is no more potent than the highest strengths of the opioid OxyContin ER (oxycodone) extended-release and extended-release morphine, in an FDA blog posted April 29.
Pharmacists more effective case managers of stroke patients than nurses
April 25th 2014Pharmacist-led care with prescribing authority substantially improved risk factors at 6 months among stroke survivors versus nurse case managers who monitored patients and provided feedback to their primary care physicians, according to a report published in the Canadian Medical Association’s journal, CMAJ.
Community-associated MRSA epidemic linked to fluoroquinolone usage
April 24th 2014Since the late 1990s, USA300, a strain of methicillin-resistant Staphylococcus aureus (MRSA), has spread across the United States, contributing to an epidemic of community-associated [CA] MRSA. The strains can persist in residential homes after infections, and appear to be linked to high usage of fluoroquinolones, according to a study published in the Proceedings for the National Academy of Sciences.
FDA requires warning of possible neurologic events after epidural corticosteroid injections
April 24th 2014FDA is requiring that drug labels for injectable corticosteroids used to treat neck and back pain must be updated to include a warning of rare but serious adverse events, including vision loss, stroke, paralysis, and death, according to a recent FDA drug safety communication.
Pharmacist pre- and post-discharge medication review equally important
April 21st 2014Pharmacists who contacted high-risk patients within 72 hours of discharge from Massachusetts General Hospital, Boston, found more than half of the patients had medication-related issues. In a different group of high-risk patients who had received inpatient interventions, 35% of patients were found to have issues after a pharmacist reviewed their medications just prior to discharge, according to Laura Carr, PharmD.
CVS sued for suspected fraudulent Rx reimbursements
April 18th 2014CVS Pharmacy is once again in hot water regarding its handling and dispensing of controlled substances-this time being sued by an insurer and 18 states that claim the pharmacy chain collected hundreds of millions for invalid prescriptions that were diverted to the black market.